Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Tofacitinib

Brand: Xeljanz®
NICE TA: 543
Indication: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA543)
Disease category: Skin
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if:
• it is used as described in NICE’s technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
• the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or
TNF alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE’s technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
Tofacitinib is only recommended if the company provides it according to the commercial arrangement.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red